Economic impact of medication non-adherence by disease groups: a systematic review
Open accessThe DOI matches its Crossref record; 98 of the 113 references it cites were found in a registry or an index; 5 of the 59 sources its claims cite were checked for support.
Abstract
OBJECTIVE: To determine the economic impact of medication non-adherence across multiple disease groups. DESIGN: Systematic review. EVIDENCE REVIEW: A comprehensive literature search was conducted in PubMed and Scopus in September 2017. Studies quantifying the cost of medication non-adherence in relation to economic impact were included. Relevant information was extracted and quality assessed using the Drummond checklist. RESULTS: Seventy-nine individual studies assessing the cost of medication non-adherence across 14 disease groups were included. Wide-scoping cost variations were reported, with lower levels of adherence generally associated with higher total costs. The annual adjusted disease-specific economic cost of non-adherence per person ranged from $949 to $44 190 (in 2015 US$). Costs attributed to 'all causes' non-adherence ranged from $5271 to $52 341. Medication possession ratio was the metric most used to calculate patient adherence, with varying cut-off points defining non-adherence. The main indicators used to measure the cost of non-adherence were total cost or total healthcare cost (83% of studies), pharmacy costs (70%), inpatient costs (46%), outpatient costs (50%), emergency department visit costs (27%), medical costs (29%) and hospitalisation costs (18%). Drummond quality assessment yielded 10 studies of high quality with all studies performing partial economic evaluations to varying extents. CONCLUSION: Medication non-adherence places a significant cost burden on healthcare systems. Current research assessing the economic impact of medication non-adherence is limited and of varying quality, failing to provide adaptable data to influence health policy. The correlation between increased non-adherence and higher disease prevalence should be used to inform policymakers to help circumvent avoidable costs to the healthcare system. Differences in methods make the comparison among studies challenging and an accurate estimation of true magnitude of the cost impossible. Standardisation of the metric measures used to estimate medication non-adherence and development of a streamlined approach to quantify costs is required. PROSPERO REGISTRATION NUMBER: CRD42015027338.
Overview
CoChat Summary
## TL;DR
This systematic review found that medication non-adherence is generally associated with higher healthcare costs across 14 disease groups, but the reported costs varied widely and could not be meaningfully pooled because of heterogeneity. Across 79 included studies, the adjusted annual disease-specific cost of non-adherence per person ranged from $949 to $44,190, and the authors concluded that standardised adherence and cost measures are needed.
## Key findings
- The review included 79 individual studies across 14 disease groups; search strategies retrieved 2768 records, 289 were full-text reviewed, and 79 were included.
- Reported annual adjusted disease-specific economic cost of non-adherence per person ranged from $949 to $44,190 (2015 US$); costs attributed to “all causes” non-adherence ranged from $5271 to $52,341.
- Across studies reporting total or total healthcare costs, 39 studies (49%) found non-adherence costs were greater than adherence costs, while 11 studies (15%) found the opposite.
- The most-used adherence metric was medication possession ratio (MPR), reported in 51 studies (63%); the next most common was proportion of days covered (PDC) at 11%.
- Quality assessment found 10 high-quality, 59 medium-quality, and 10 low-quality studies; no full economic evaluation was conducted in any included study.
## Methods
- Design: Systematic review conducted according to PRISMA and registered in PROSPERO (CRD42015027338).
- Data/sample: Searches were run in PubMed and Scopus in September 2017, with no publication date or language restrictions; included studies had to report the monetary cost of medication non-adherence for any disease state and provide original data.
- Main analysis: Two reviewers appraised studies using a modified Drummond checklist; costs were converted to 2015 US$, extracted by outcome indicator, and the authors attempted but could not perform a meta-analysis because of heterogeneity and missing statistical parameters.
## Limitations
- The paper states that a meta-analysis could not be performed because of heterogeneity in study design and lack of required statistical parameters, particularly standard deviations.
- The authors note that differences in methodological strategies, adherence definitions, and cost indicators made comparison across studies difficult and limited estimation of the true magnitude of costs.
- Evident from the text: the evidence base was dominated by US studies (66 of 79; 83%), and many studies were partial economic evaluations rather than full economic evaluations, which limits generalisability and comparability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
4 Valid · 0 Not valid · 58 Not checked · 72 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“While Zhao et al80 categorised participants into adherence subgroups, finding that total healthcare costs were lower for the non-adherent population.”
§ Economic impact of medication non-adherence by disease groups: a systematic review > Results > Cost of medication non-adherence via disease group
What the sources say
- Supportedcites [80] Zhao, 2014, Associations between statin adherence level, health care costs, and utilization, J Manag Care Spec Pharm source
The Statistical Analysis section divides participants into statin-adherence groups. The results report that the lowest-adherence group (MPR <40%) had lower estimated total health care costs over one year than every higher-adherence group; the difference was statistically significant for all but the 70%–79% group. This supports the citing sentence’s comparison, although the paper uses a specific low-adherence group rather than a single category of all non-adherent patients. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“One study measured the influence of medication non-adherence on direct healthcare costs in metabolic conditions, reporting an unadjusted attributable total cost of $138 525.54”
§ Economic impact of medication non-adherence by disease groups: a systematic review > Results > Cost of medication non-adherence via disease group
What the sources say
- Partly supportedcites [54] matched to “Association of cinacalcet adherence and costs in patients on dialysis” (2011) sourceExperimental — accuracy not yet measured
The Methods and Results report an analysis of cinacalcet adherence and direct healthcare costs in dialysis patients with secondary hyperparathyroidism, including unadjusted 12-month costs. The Results refer to a table of mean costs, but the values are absent from our copy; no passage verifies the claimed $138,525 unadjusted attributable total cost. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The findings were that, for all levels of non-adherence, costs of non-adherence were higher for Medicare supplemental patients.45”
§ Economic impact of medication non-adherence by disease groups: a systematic review > Results > Cost of medication non-adherence via disease group
What the sources say
- Partly supportedcites [45] Halpern, 2011, The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis, J Manag Care Pharm sourceExperimental — accuracy not yet measured
The medical-cost results (page unavailable) report higher adjusted costs with low versus high adherence in both groups, with a larger percentage increase in Medicare Advantage patients (18%) than commercial patients (12%). Moderate adherence was also associated with higher costs in the Medicare Advantage group, but not significantly in the commercial group. The claim calls these patients “Medicare supplemental” rather than Medicare Advantage and does not specify that the comparison concerns adjusted percentage increases, so its broader cost comparison is not established. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Seventy-nine individual studies assessing the cost of medication non-adherence across 14 disease groups were included.”
§ Economic impact of medication non-adherence by disease groups: a systematic review > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted total cost of non-adherence across all disease groups ranged from $949 to $52 341, while the unadjusted total cost ranged from $669 to $162 699.”
§ Economic impact of medication non-adherence by disease groups: a systematic review > Results > Medication non-adherence and costs
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
67 more claims
Create a free account to see all 134 claims and every source verdict.
- It may state two separate claims as one. 43
- Probably not a substantial claim. 28
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Medication non-adherence is a widespread problem that causes high costs worldwide [5–10].”
From Medication adherence influencing factors—an (updated) overview of systematic reviews (2019) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Furthermore, a person-centered approach predicts better outcomes, such as fewer relapses, suicide and overall mortality [91].”
From Therapeutic Adherence of People with Mental Disorders: An Evolutionary Concept Analysis (2023) · cites this paper as [91]
Experimental — accuracy not yet measuredIn the citing paper
“Only then will it be possible to contribute to the improvement of clinical and social outcomes, generate commitment, and guarantee a quality of services that translates into increased adherence rates and reduced number of hospitalizations and all associated costs (including pharmacy costs and inpatient and outpatient costs) [91].”
From Therapeutic Adherence of People with Mental Disorders: An Evolutionary Concept Analysis (2023) · cites this paper as [91]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. P. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,648
Guidelines for authors and peer reviewers of economic submissions to the BMJ
Drummond, M. F., & Jefferson, T. O. (1996) · BMJ · doi:10.1136/bmj.313.7052.275 · Cited by 1,827
Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost
Sokol, M. C., McGuigan, K. A., Verbrugge, R. R., & Epstein, R. S. (2005) · Medical Care · doi:10.1097/01.mlr.0000163641.86870.af · Cited by 1,729 · cited 4×
“The adjusted cost of medication non-adherence was reported in 14 studies with an estimated range of $5271–52 341.(10) 29 31 56 58–60 70 75 76 83 84 86 90 Sokol et al(10) reported the all-cause cost of non-adherence through subgroup analysis of disease states and MPR levels, while Pittman et al(60) reported only using…”
BackgroundMethodInfluentialInterventions for helping patients to follow prescriptions for medications
Haynes, R., McDonald, H., Garg, A., & Montague, P. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011 · Cited by 911
Hess, L. M., Raebel, M. A., Conner, D. A., & Malone, D. C. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h018 · Cited by 756
Gilmer, T. P., Dolder, C. R., Lacro, J. P., Folsom, D. P., Lindamer, L., Garcia, P., & Jeste, D. V. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.692 · Cited by 603 · cited 2×
“65 81 98 Six studies used adjusted costs, finding that the total annual cost of non-adherence per patient ranged from $3252 to $19 363.(23) 25 58 59 72 90 Bagalman et al(25) focused primarily on”
BackgroundResult
Cited by
SCOPE 2021: a new scorecard for osteoporosis in Europe
Kanis, J. A., Norton, N., Harvey, N. C., Jacobson, T., Johansson, H., Lorentzon, M., McCloskey, E. V., Willers, C., & Borgström, F. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-020-00871-9 · Cited by 714
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 492
Medication adherence influencing factors—an (updated) overview of systematic reviews
Gast, A., & Mathes, T. (2019) · Systematic Reviews · doi:10.1186/s13643-019-1014-8 · Cited by 560
Kvarnström, K., Westerholm, A., Airaksinen, M., & Liira, H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071100 · Cited by 470
Walsh, C. A., Cahir, C., Tecklenborg, S., Byrne, C., Culbertson, M. A., & Bennett, K. E. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14075 · Cited by 269
“A recent review on the economic burden of medication non‐adherence cited the wide variability in adherence measurement and study methodologies as a barrier to meta‐analysis.(114) This is evident in the current review.”
BackgroundCharoo, N. A., Barakh Ali, S. F., Mohamed, E. M., Kuttolamadom, M. A., Ozkan, T., Khan, M. A., & Rahman, Z. (2020) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2020.1764027 · Cited by 268
Wang, T., Tan, J.-Y. (., Liu, X.-L., & Zhao, I. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-062158 · Cited by 261
Cross, A. J., Elliott, R. A., Petrie, K., Kuruvilla, L., & George, J. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012419.pub2 · Cited by 249
Pons-Faudoa, F. P., Ballerini, A., Sakamoto, J., & Grattoni, A. (2019) · Biomedical Microdevices · doi:10.1007/s10544-019-0389-6 · Cited by 210
“This results in an annual economic burden of $100 billion USD in health care services (Cutler et al. 2018; Kini and Ho 2018; Pagès-Puigdemont et al. 2016; Oung et al. 2017).”
BackgroundReligioni, U., Barrios-Rodríguez, R., Requena, P., Borowska, M., & Ostrowski, J. (2025) · Medicina · doi:10.3390/medicina61010153 · Cited by 215
Sakib, M. N., Zolfagharian, M., & Yazdanparast, A. (2020) · Journal of Retailing and Consumer Services · doi:10.1016/j.jretconser.2019.01.002 · Cited by 210
Babel, A., Taneja, R., Mondello Malvestiti, F., Monaco, A., & Donde, S. (2021) · Frontiers in Digital Health · doi:10.3389/fdgth.2021.669869 · Cited by 199
“As mentioned previously (55), medication non-adherence is associated with substantial increases in patient costs, so it is of utmost importance to establish whether AI and AI-assisted interventions actually increase or decrease the costs associated with non-adherence in future, well-designed…”
BackgroundInfluentialTelepharmacy Services: Present Status and Future Perspectives: A Review
Baldoni, S., Amenta, F., & Ricci, G. (2019) · Medicina · doi:10.3390/medicina55070327 · Cited by 190
“Moreover, 10% of hospitalizations in older adults are attributable to noncompliance to prescription [46].”
BackgroundHamrahian, S. M., Maarouf, O. H., & Fülöp, T. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s368784 · Cited by 170
“These steps carry the risk of increased emergency department visits, leading to unnecessary hospitalizations and further increase in health-care costs.(62,63)”
BackgroundMedication adherence in hypertension
Poulter, N. R., Borghi, C., Parati, G., Pathak, A., Toli, D., Williams, B., & Schmieder, R. E. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002294 · Cited by 164
“The number of studies assessing the economic impact of medication nonadherence is limited and they are of varying quality [91], whereas many of them have limitations, such as their retrospective observational nature and the potential impact of the ‘healthy adherer effect’, that is, the possibility that patients with b…”
BackgroundHall, A. M., Scurrey, S. R. M., Pike, A. E., Albury, C., Richmond, H., Matthews, J. J., Toomey, E. C., Hayden, J. A., & Etchegary, H. (2019) · Implementation Science · doi:10.1186/s13012-019-0884-4 · Cited by 169
Parekh, N., Ali, K., Stevenson, J. M., Davies, G., Schiff, R., van der Cammen, T. J. M., Harchowal, J., Raftery, J. P., Rajkumar, C., & on behalf of the PRIME study group (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13613 · Cited by 171
Salmasi, S., Loewen, P. S., Tandun, R., Andrade, J. G., & Vera, M. A. D. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-034778 · Cited by 179
Estimating proportion of days covered (PDC) using real-world online medicine suppliers’ datasets
Prieto-Merino, D., Mulick, A., Armstrong, C., Hoult, H., Fawcett, S., Eliasson, L., & Clifford, S. (2021) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-021-00385-w · Cited by 137
“to treatment can adversely affect people’s health outcomes, present a significant barrier to optimal care and can increase healthcare costs [2, 3].”
BackgroundMedication adherence in cardiovascular medicine
Simon, S. T., Kini, V., Levy, A. E., & Ho, P. M. (2021) · BMJ · doi:10.1136/bmj.n1493 · Cited by 157
Tran, S., Smith, L., El-Den, S., & Carter, S. (2022) · JMIR mHealth and uHealth · doi:10.2196/30671 · Cited by 121
“This results in substantial economic and social costs to the patient and the country [3].”
BackgroundNavigating the Wild West of Medication Adherence Reporting in Specialty Pharmacy
Canfield, S. L., Zuckerman, A. D., Anguiano, R. H., Jolly, J. A., DeClercq, J., Wascher, M., Choi, L., Knox, S., & Mitchell, D. G. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.10.1073 · Cited by 143
Bingham, J. M., Black, M., Anderson, E. J., Li, Y., Toselli, N., Fox, S., Martin, J. R., Axon, D. R., & Silva-Almodóvar, A. (2021) · Annals of Pharmacotherapy · doi:10.1177/1060028020950726 · Cited by 120
“8,14 Adherence interventions with a positive impact on either MPR or PDC identified in this review included the following: (1) interventions that engaged patients in conversation to identify and resolve barriers to medication nonadherence,16-19 (2) adoption of a plan to help resolve their medication adherence issues,1…”
BackgroundMethodBanerjee, A., Benedetto, V., Gichuru, P., Burnell, J., Antoniou, S., SCHILLING, R. J., Strain, W. D., Ryan, R. P., Watkins, C. L., Marshall, T. P., et al. (2019) · Heart · doi:10.1136/heartjnl-2019-315307 · Cited by 132
Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing
Lane, D., Lawson, A., Burns, A., Azizi, M., Burnier, M., Jones, D. J. L., Kably, B., Khunti, K., Kreutz, R., Patel, P., et al. (2022) · Hypertension · doi:10.1161/hypertensionaha.121.17596 · Cited by 111
Maffoni, M., Traversoni, S., Costa, E. M., Midão, L., Kardas, P., Kurczewska-Michalak, M., & Giardini, A. (2020) · European Geriatric Medicine · doi:10.1007/s41999-020-00313-2 · Cited by 119
Ismail, H., Marshall, V. D., Patel, M. R., Tariq, M., & Mohammad, R. A. (2021) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2021.11.013 · Cited by 93
Deprescribing: Future directions for research
Thompson, W., Reeve, E., Moriarty, F., Maclure, M., Turner, J. P., Steinman, M. A., Conklin, J., Dolovich, L. R., McCarthy, L. M., & Farrell, B. J. (2018) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2018.08.013 · Cited by 84
Konstantinou, P., Kassianos, A. P., Georgiou, G., Panayides, A., Papageorgiou, A., Almas, I., Wozniak, G., & Karekla, M. (2020) · Translational Behavioral Medicine · doi:10.1093/tbm/ibaa118 · Cited by 89
Impact of pictograms on medication adherence: A systematic literature review
Sletvold, H., Sagmo, L. A. B., & Torheim, E. A. (2019) · Patient Education and Counseling · doi:10.1016/j.pec.2019.12.018 · Cited by 97
Wu, D., Lowry, P. B., Zhang, D., & Tao, Y. (2022) · Journal of Medical Internet Research · doi:10.2196/42941 · Cited by 124
“Poor patient adherence can obscure a clinician’s assessment of therapeutic effectiveness and result in avoidable hospitalization, increased mortality risk, and increased health care costs [5,8,16].”
InfluentialMedication Adherence Trajectories: A Systematic Literature Review
Alhazami, M., Pontinha, V. M., Patterson, J. A., & Holdford, D. A. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.9.1138 · Cited by 120
Digital therapeutics in the clinic
Phan, P., Mitragotri, S., & Zhao, Z. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10536 · Cited by 104
“approximately $50,000 per patient when non-selectively analyzed by disease type.(98) The use of DTx could potentially improve adherence to therapies and lead to savings by reducing emergency hospital visits and overall total cost of care.”
BackgroundTorres-Robles, A., Benrimoj, S. I., Gastelurrutia, M. Á., Martínez, F. M., Zorrilla, T. P., Pérez-Escamilla, B., Rogers, K. D., Valverde-Merino, M. I., Doval, R. V., & García‐Cárdenas, V. (2021) · BMJ Quality & Safety · doi:10.1136/bmjqs-2020-011671 · Cited by 84
Self-citationSteroid Phobia: A Review of Prevalence, Risk Factors, and Interventions
Contento, M. N., Cline, A. E., & Russo, M. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00623-6 · Cited by 71
“Non-adherence undermines the efficacy of any treatment, resulting in poor clinical outcomes, high healthcare costs, inpatient admissions, and treatment escalation [1].”
BackgroundGomes, D., Plácido, A. I., Mó, R., Simões, J. F. F. L., Amaral, O. P., Fernandes, I., Lima, F., Morgado, M., Figueiras, A., Herdeiro, M. T., et al. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17010200 · Cited by 82
“According with Morris and Schulz [29], nonadherence to medication occurs due to the influence of friendship and family on the clinical status of the patient and can range from 40% to 75% in the elderly [30,31].”
BackgroundChen, J., Tian, Y., Yin, M., Lin, W., Tuersun, Y., Li, L., Yang, J., Wu, F., Kan, Y., Li, X., et al. (2022) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2022.111105 · Cited by 87
Ge, L., Heng, B. H., & Yap, C. W. (2023) · BMC Health Services Research · doi:10.1186/s12913-023-09904-8 · Cited by 83
“As medication non-adherence significantly compromises the effectiveness of treatment, it has remarkable impacts on individuals, healthcare system, and society, resulting in suboptimal health outcomes, increased healthcare utilisation and cost, and higher mortality [3–7].”
BackgroundMonaco, A., Palmer, K., Marengoni, A., Maggi, S., Hassan, T. A., & Donde, S. S. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01533-z · Cited by 70
Digital Pills with Ingestible Sensors: Patent Landscape Analysis
Litvinova, O., Klager, E., Tzvetkov, N. T., Kimberger, O., Kletečka-Pulker, M., Willschke, H., & Atanasov, A. G. (2022) · Pharmaceuticals · doi:10.3390/ph15081025 · Cited by 64
“Non-adherence is thus a critical clinical and economic problem [5].”
BackgroundA systematic review of factors associated with side‐effect expectations from medical interventions
Smith, L., Webster, R., & Rubin, G. J. (2020) · Health Expectations · doi:10.1111/hex.13059 · Cited by 62
Device use errors with soft mist inhalers: A global systematic literature review and meta-analysis
Navaie, M., Dembek, C., Cho‐Reyes, S., Yeh, K., & Celli, B. R. (2020) · Chronic Respiratory Disease · doi:10.1177/1479973119901234 · Cited by 56
“7) M: 65 (93) F: 5 (7) COPD GOLD I: 3 (4) GOLD II: 6 (9) GOLD III: 8 (11) GOLD IV: 53 (76) Bournival et al.”
User-friendly and industry-integrated AI for medicinal chemists and pharmaceuticals
Kapustina, O., Burmakina, P., Gubina, N., Serov, N., & Vinogradov, V. V. (2024) · Artificial Intelligence Chemistry · doi:10.1016/j.aichem.2024.100072 · Cited by 88
Gossec, L., Moltó, A., Romand, X., Puyraimond‐Zemmour, D., Lavielle, M., Beauvais, C., Senbel, É., Flipo, R., Pouplin, S., Richez, C., et al. (2018) · Joint Bone Spine · doi:10.1016/j.jbspin.2018.08.006 · Cited by 58
Development of 3D-printed subcutaneous implants using concentrated polymer/drug solutions
Picco, C. J., Utomo, E., McClean, A., Domínguez‐Robles, J., Anjani, Q. K., Volpe‐Zanutto, F., McKenna, P. E., Acheson, J. G., Malinova, D., Donnelly, R. F., et al. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122477 · Cited by 56
Lawson, A. J., Hameed, M. A., Brown, R., Cappuccio, F. P., George, S., Hinton, T., Kapil, V., Lenart, J., Lobo, M. D., Martin, U., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002398 · Cited by 62
“Medication wastage because of nonadherence places an enormous cost burden on the healthcare system [24].”
BackgroundPirri, S., Lorenzoni, V., & Turchetti, G. (2020) · BMC Health Services Research · doi:10.1186/s12913-020-05544-4 · Cited by 59
Persistence as a Robust Indicator of Medication Adherence-Related Quality and Performance
Menditto, E., Cahir, C., Malo, S., Aguilar‐Palacio, I., Almada, M., Costa, E. M., Giardini, A., Gil‐Peinado, M., Mesquida, M. M., Mucherino, S., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18094872 · Cited by 54
“Integrating pharmacy claims data with more complete data sources, such as clinical and health outcomes, would provide information on the clinical indication for each medication and reasons for medication changes or cessation [39,40].”
BackgroundWagnew, F., Gray, D. J., Tsheten, T., Kelly, M., Clements, A., & Alene, K. A. (2023) · Nutrition Reviews · doi:10.1093/nutrit/nuad120 · Cited by 67
“10,11 A recent meta-analysis also reported that missing more than 10% of doses of the prescribed TB drugs causes a 6-fold higher risk of poor treatment outcomes.”
BackgroundGalozy, A., Nowaczyk, S., Sant’Anna, A., Ohlsson, M., & Lingman, M. (2020) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2020.104092 · Cited by 51
Yoon, S., Kwan, Y. H., Yap, W. L., Lim, Z. Y., Phang, J. K., Loo, Y. X., Aw, J., & Low, L. L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1124297 · Cited by 63
“, the annual disease-specific economic cost associated with nonadherence ranged from US$949 to US$44,190 per person (Cutler et al., 2018).”
BackgroundTherapeutic Adherence of People with Mental Disorders: An Evolutionary Concept Analysis
Laranjeira, C., Carvalho, D., Valentim, O., Moutinho, L., Morgado, T., Tomás, C., Gomes, J., & Querido, A. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20053869 · Cited by 45
“Furthermore, a person-centered approach predicts better outcomes, such as fewer relapses, suicide and overall mortality [91].”
BackgroundBrar Prayaga, R., Agrawal, R., Nguyen, B., Jeong, E. W., Noble, H. K., Paster, A., & Prayaga, R. S. (2019) · JMIR mHealth and uHealth · doi:10.2196/15771 · Cited by 45
“The most commonly identified SDOH in the United States are housing, income, food, transportation, education, race/ethnicity, and unemployment [27,28].”
BackgroundWei, Q., Zhou, J., Li, H., Wang, L., Wu, Y., Ma, A., & Guan, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1156081 · Cited by 60
“Not only does poor adherence results in limited effect of disease control, but it also imposes a huge disease burden on the healthcare system due to possible associated complications and adverse events (Cutler et al., 2018).”
BackgroundSmartphone Apps for Diabetes Medication Adherence: Systematic Review
Islam, S. M. S., Mishra, V., Siddiqui, M. U., Moses, J. C., Adibi, S., Nguyen, L., & Wickramasinghe, N. S. (2022) · JMIR Diabetes · doi:10.2196/33264 · Cited by 57
“Nonadherence to medical therapy also results in increased absenteeism, hospitalization risk, and need for health care, which have an enormous economic impact on individuals and society [15,16].”
BackgroundMauro, J., Mathews, K., & Sredzinski, E. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.11.1244 · Cited by 57
Dima, A. L., Allemann, S. S., Dunbar‐Jacob, J. M., Hughes, D. A., Vrijens, B., & Wilson, I. B. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14659 · Cited by 52
The Impact of Digital Therapeutics on Current Health Technology Assessment Frameworks
Yan, K., Balijepalli, C., & Druyts, E. (2021) · Frontiers in Digital Health · doi:10.3389/fdgth.2021.667016 · Cited by 46
“Non-adherence to traditional pharmaceutical drugs is already a common issue contributing costs upwards of $50,000 per patient per year (21).”
BackgroundKam, N., Perera, K., Zomer, E., Liew, D., & Ademi, Z. (2020) · PharmacoEconomics · doi:10.1007/s40273-020-00948-w · Cited by 45
Leavey, G., McGrellis, S., Forbes, T., Thampi, A., Davidson, G., Rosato, M., Bunting, B., Divin, N., Hughes, L., Toal, A., et al. (2019) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-019-01684-z · Cited by 41
Pécout, C., Pain, É., Chekroun, M., Champeix, C., Kulak, C., Prieto, R., van Vugt, J., Gilchrist, K., & Lainé-Pellet, A.-F. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18136697 · Cited by 42
“25 billion in Europe and USD 290 billion in the USA [32].”
BackgroundKardas, P., Bennett, B. L., Borah, B. J., Burnier, M., Daly, C., Hiligsmann, M., Menditto, E., Peterson, A. M., Slejko, J. F., Tóth, K., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1444012 · Cited by 64
Multilevel factors predict medication adherence in rheumatoid arthritis: a 6-month cohort study
Balsa, A., de Yébenes, M. J. G., Carmona, L., Courel, L. G., Mendizábal, J., Restrepo, J., Fábregas, D., de Buruaga, J. A. S., Etxebarrieta, J. D., Zavaleta, N. R., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221163 · Cited by 53
Studer, C. M., Linder, M., & Pazzagli, L. (2023) · Journal of Health Population and Nutrition · doi:10.1186/s41043-023-00459-2 · Cited by 63
Audrain‐Pontevia, A., Menvielle, L., & Ertz, M. (2019) · Journal of Medical Internet Research · doi:10.2196/14006 · Cited by 41
“Defined as the extent to which a patient’s behavior coincides with the medical or health advice given by a health care specialist, patient compliance is of particularly critical importance for people with chronic health problems [1-3].”
BackgroundTorres-Robles, A., Wiecek, E., Tonin, F. S., Benrimoj, S. I., Fernández-Llimós, F., & García‐Cárdenas, V. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01454 · Cited by 52
Self-citationMancia, G., Cappuccio, F. P., Burnier, M., Coca, A., Persu, A., Borghi, C., Kreutz, R. H., & Sanner, B. M. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13678 · Cited by 67
Gender Based Cognitive Determinants Of Medication Adherence In Older Adults With Chronic Conditions
Mahmoodi, H., Nahand, F. J., Shaghaghi, A., Shooshtari, S., Jafarabadi, M. A., & Allahverdipour, H. (2019) · Patient Preference and Adherence · doi:10.2147/ppa.s219193 · Cited by 51
Telepharmacy and Quality of Medication Use in Rural Areas, 2013–2019
Pathak, S., Haynes, M., Qato, D. M., & Urick, B. Y. (2020) · Preventing Chronic Disease · doi:10.5888/pcd17.200012 · Cited by 60
Lauffenburger, J. C., Yom‐Tov, E., Keller, P. A., McDonnell, M. E., Crum, K. L., Bhatkhande, G., Sears, E. S., Hanken, K. E., Bessette, L. G., Fontanet, C. P., et al. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01028-5 · Cited by 56
Wang, Y., Li, X., Jia, D., Lin, B., Fu, B., Qi, B., & Zhang, Z. (2021) · BMC Geriatrics · doi:10.1186/s12877-021-02247-1 · Cited by 45
Hein, A.-E., Vrijens, B., & Hiligsmann, M. (2020) · Frontiers in Medical Technology · doi:10.3389/fmedt.2020.604183 · Cited by 39
“Furthermore, health systems and societies are confronted with significant inefficiencies, resulting in higher costs and overall financial burden (12–15).”
BackgroundIngestible electronic sensors to measure instantaneous medication adherence: A narrative review
Chai, P. R., Vaz, C., Goodman, G. R., Albrechta, H., Huang, H., Rosen, R. K., Boyer, E. W., Mayer, K. H., & O’Cleirigh, C. M. (2022) · Digital Health · doi:10.1177/20552076221083119 · Cited by 40
“A meta-analysis from 2018 calculated the all-cause annual cost per person for medication nonadherence to be between $5271 and $52,341.(5) In the US, 69% of hospital admissions due to medication-related events are a result of medication nonadherence.”
Balouchi, A., Rafsanjani, M. H., Al-Mutawaa, K., Naderifar, M., Rafiemanesh, H., Ebadi, A., Ghezeljeh, T. N., Shahraki-Mohammadi, A., & Al‐Mawali, A. (2021) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2021.101069 · Cited by 49
Sigglekow, F., Horsburgh, S., & Parkin, L. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242424 · Cited by 43
Yang, C., Zhu, S., Lee, D., & Chair, S. Y. (2021) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2021.104154 · Cited by 51
Poor Adherence to Medical and Dietary Treatments in Adult Patients With Eosinophilic Esophagitis
Haasnoot, M. L., Safi, S., & Bredenoord, A. J. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001850 · Cited by 43
“Being adherent is not only beneficial for the individual patient in terms of disease outcomes, but poor treatment adherence is also associated with increased health care costs (27).”
BackgroundMartin, L. R., Feig, C., Maksoudian, C. R., Wysong, K. E., & Faasse, K. (2018) · Patient Preference and Adherence · doi:10.2147/ppa.s155971 · Cited by 48
Suhail, M., Saeed, H., Saleem, Z., Younas, S., Hashmi, F. K., Rasool, M. F., Islam, M. F., & Imran, I. (2021) · Health and Quality of Life Outcomes · doi:10.1186/s12955-021-01761-5 · Cited by 52
Zijp, T. R., Touw, D. J., & van Boven, J. F. M. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s240443 · Cited by 41
Using Dispensing Data to Evaluate Adherence Implementation Rates in Community Pharmacy
Torres-Robles, A., Wiecek, E., Cutler, R., Drake, B., Benrimoj, S. I., Fernandez-Llimos, F., & Garcia-Cardenas, V. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00130 · Cited by 33
Self-citationUse of the transtheoretical model in medication adherence: A systematic review
Imeri, H., Toth, J. M., Arnold, A. D., & Barnard, M. (2021) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2021.07.008 · Cited by 41
Tola, H. H., Holakouie‐Naieni, K., Mansournia, M. A., Yaseri, M., Tesfaye, E., Mahamed, Z., & Sisay, M. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-56553-1 · Cited by 46
Yang, C., Hui, Z., Zeng, D., Liu, L., & Lee, D. T. F. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-033431 · Cited by 34
Bond, Z., Scanlon, T., & Judah, G. (2021) · Healthcare · doi:10.3390/healthcare9101282 · Cited by 33
“In addition to the negative health impact of low adherence, non-adherence also results in significant healthcare costs, with one review estimating the annual per-patient cost of non-adherence to CVD medications (due to additional medical costs, unnecessary hospitalisations, and primary care visits) to range from $3347…”
BackgroundExploring a New Theoretical Model to Explain the Behavior of Medication Adherence
Unni, E., & Bae, S. (2022) · Pharmacy · doi:10.3390/pharmacy10020043 · Cited by 49
“One study showed the annual economic cost of cancer medication non-adherence at $119,416 per patient [14].”
BackgroundMarquina, C., Zomer, E., Vargas-Torres, S., Zoungas, S., Ofori-Asenso, R., Liew, D., & Ademi, Z. (2020) · PharmacoEconomics · doi:10.1007/s40273-020-00936-0 · Cited by 34
“Lower adherence rates have been shown to lead to worse health outcomes and increased costs for healthcare systems [66]; however, adherence was only modelled in six out of seven studies evaluating the cost-effectiveness of the polypill [27, 34, 41, 52, 54, 55] and in none of the studies analysing other interventions in…”
BackgroundTreatment Discontinuation or Interruption in Pulmonary Arterial Hypertension
Narechania, S., Torbic, H., & Tonelli, A. R. (2019) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248419877409 · Cited by 36
“Although we know that medication nonadherence in other chronic diseases leads to increased health-care costs, the economic impact of medication nonadherence in PAH has not been directly studied.(38) The white paper by express scripts estimated that higher adherence in patients with PAH led to lower medical expenses fo…”
BackgroundKim, H., Alten, R., Cummings, F. J. R., Danese, S., D’Haens, G., Emery, P., Ghosh, S., Gilletta, C., Lee, J. H., Lindsay, J. O., et al. (2021) · mAbs · doi:10.1080/19420862.2020.1868078 · Cited by 37
“Irrational use of medicines – including poor adherence, off-label use, prescribing inefficiency, and medicine wastage – places a significant cost burden on healthcare systems.(120,121) Medicines offering increased convenience for patients might improve adherence,”
BackgroundEllis, J. D., Struble, C. A., Fodor, M. C., Cairncross, M., Lundahl, L. H., & Ledgerwood, D. M. (2020) · Behaviour Research and Therapy · doi:10.1016/j.brat.2020.103781 · Cited by 35
Mangin, D. A., Risdon, C., Lamarche, L., Langevin, J., Ali, A., Parascandalo, J., Stephen, G., & Trimble, J. (2019) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098619838796 · Cited by 29
Andreae, S. J., Andreae, L. J., Cherrington, A., Richman, J., & Safford, M. M. (2020) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2020.100653 · Cited by 26
The Need to Develop Standard Measures of Patient Adherence for Big Data: Viewpoint
Kardas, P., Aguilar‐Palacio, I., Almada, M., Cahir, C., Costa, E. M., Giardini, A., Malo, S., Mesquida, M. M., Menditto, E., Midão, L., et al. (2020) · Journal of Medical Internet Research · doi:10.2196/18150 · Cited by 38
“Lack of standardized comparable measures of adherence is one of the major barriers to the objective selection of the most effective and cost-effective interventions [2] and the scaling-up of the best practice.”
BackgroundKhoiry, Q. A., Alfian, S. D., van Boven, J. F. M., & Abdulah, R. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1104510 · Cited by 43
“Articles, regardless paid (subscription) or free (open access), were eligible if they met the following inclusion criteria: (1) experimental and observational studies focusing on medication adherence as a primary outcome using a self-reported instrument; (2) performed among patients with hypertension, diabetes mellitu…”
MethodInterventions to enhance medication adherence in pregnancy- a systematic review
Davies, A. K., Mullin, S., Chapman, S., Barnard, K., Bakhbakhi, D., Ion, R., Neuberger, F. E. M., Standing, J. P., Merriel, A., Fraser, A., et al. (2023) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-022-05218-5 · Cited by 36
“A recent systematic review has highlighted that despite the evidence that medication non-adherence places a significant cost burden on healthcare systems, research assessing the economic impact of medication non-adherence is limited and of varying quality [60].”
BackgroundMaksyutynska, K., Stogios, N., Prasad, F., Gill, J., Hamza, Z., De, R., Smith, E., Horta, A., Goldstein, B. I., Korczak, D. J., et al. (2024) · Psychological Medicine · doi:10.1017/s0033291724000345 · Cited by 41
Adherence to treatment in dermatology: Literature review
Lo, A., Lovell, K. K., Greenzaid, J. D., Oscherwitz, M. E., & Feldman, S. R. (2024) · JEADV Clinical Practice · doi:10.1002/jvc2.379 · Cited by 44
Printing of personalized medication using binder jetting 3D printer
Rahman, Z., Charoo, N. A., Kuttolamadom, M. A., Asadi, A. A., & Khan, M. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819178-1.00046-0 · Cited by 31
Mortelmans, L., Baetselier, E. D., Goossens, E., & Dilles, T. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18137031 · Cited by 34
(2019) · doi:10.2147/ppa.s230921 · Cited by 31
“Conversely, poor adherence is associated with treatment failure and a relapse of disease.(5) A recent systematic review reported that medication non-adherence is considered as a major cost burden on the healthcare system.”
Background
Metadata
- Authors
- Cutler, R. L., Fernandez-Llimos, F., Frommer, M., Benrimoj, C., & Garcia-Cardenas, V.
- Affiliations
- University of Technology Sydney (AU)
- Department of Social Pharmacy Faculty of Pharmacy, Research Institute for Medicines (iMed.ULisboa), University of Lisbon, Lisbon, Portugal
- The University of Sydney (AU)
- Graduate School of Health, University of Technology Sydney, Sydney, New South Wales, Australia
- Corresponding author
- Cutler, Rachelle Louise
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2018-01
- Volume
- 8
- Issue
- 1
- Pages
- e016982
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC5780689
- OpenAlex
- W2790318238
- Cited by
- 900
- References
- 113
- Citations by year
- 2026: 83 · 2025: 111 · 2024: 159 · 2023: 134 · 2022: 112 · 2021: 124 · 2020: 91 · 2019: 68 · 2018: 16
- FWCI
- 16.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- OPUS - Open Publications of UTS Scholars (University of Technology Sydney) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Australian Government
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- medication non-adherence, economic burden, health care costs, medication possession ratio, adherence measurement, health policy
- MeSH terms
- Cost-Benefit Analysis, Disease, Drug Therapy, Humans, Drug Monitoring, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.